---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-396644"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-09-21T20:01:07+00:00"
generated_at: "2026-09-21T20:02:08.717002+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sangamo sells Fabry gene therapy ST-920 to PTC for $111M cash; Nasdaq delisting Sept 27

## Summary
- Completed Sept 17, 2026 sale of ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111M cash at close.
- Up to $100M in additional milestone-based contingent consideration; PTC assumes specified liabilities.
- Court approved sale Sept 2, 2026 (Docket No. 426) following Aug 10 auction where PTC was successful bidder.
- Nasdaq delisting effective Sept 27, 2026 after Form 25 filed Sept 17; stock trades OTC under SGMOQ.
- Company operates as debtor-in-possession in Chapter 11 Case No. 26-10989 (Delaware Bankruptcy Court).

## SEC filing metadata
- accession: 0001193125-26-396644
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-09-21T20:01:07+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.03, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/0001193125-26-396644-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/d178611d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-396644
- JSON: https://secwatch.observer/filing/0001193125-26-396644.json
- Plain text: https://secwatch.observer/filing/0001193125-26-396644.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.